Key result
Resveratrol protects in a dose-dependent manner against the development of pulmonary arterial hypertension induced through monocrotaline, normoxia, and hypoxia models.
Why the study?
Resveratrol has shown protective effects in pulmonary arterial hypertension, but its dose-related effects across different models required investigation.
Does resveratrol protect against the development of pulmonary arterial hypertension in preclinical models?
Systematic Review (n=11)
Does resveratrol protect against the development of pulmonary arterial hypertension in preclinical models?
Resveratrol demonstrates dose-dependent protective effects against the development of pulmonary arterial hypertension in preclinical models.
May support resveratrol for PAH prevention; extends preclinical data but leaves open human translation.
BACKGROUND: Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have demonstrated that resveratrol possesses a protective effect on the mechanisms related to the genesis of the PAH-induced by different models. OBJECTIVE: This study aimed to investigate the dose-related effects of resveratrol in different models of pulmonary arterial hypertension. METHODS: To identify eligible papers, we performed a systematic literature search on Scielo, Pub- Med, and Scholar Google. The research was limited to articles written in English in the last 10 years. We used the following descriptors to search: Pulmonary Arterial Hypertension and Resveratrol, OR Resveratrol, and Animal models of Pulmonary Arterial Hypertension, OR Resveratrol, and in vitro models of Pulmonary Arterial Hypertension. RESULTS: 1724 studies were identified through the descriptors used, fifty-five studies with different models of pulmonary arterial hypertension were selected for the full review, forty-four were excluded after application of exclusion and inclusion criteria, totalizing eleven studies included in this systematic review. CONCLUSION: The results showed that resveratrol, at low and high doses, protects in a dosedependent manner against the development of PAH induced through monocrotaline, normoxia and hypoxia models. In addition to having chemopreventive, anti-inflammatory, antioxidant and antiproliferative properties. In the case of PAH-related myocardial injury, resveratrol protects cells from apoptosis, thus working as an antiapoptotic agent.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2019) conducted a systematic review in Pulmonary Arterial Hypertension (n=11). Resveratrol vs. Control/Vehicle was evaluated on Development of pulmonary arterial hypertension (right ventricular systolic pressure, right ventricular hypertrophy, vascular remodeling). Resveratrol protects in a dose-dependent manner against the development of pulmonary arterial hypertension induced through monocrotaline, normoxia, and hypoxia models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: